31 01, 2023

We are proud to announce our ISO 13485:2016 certification

2023-03-10T08:28:14+01:00January 31st, 2023|biomarkers, ISO 13485, microRNA, quality, smallRNA|Comments Off on We are proud to announce our ISO 13485:2016 certification

Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates that TAmiRNAs quality management system meets the most current regulatory requirements applicable to the medical device industry. "We are very proud of this certification as it demonstrates the commitment of our team to meet customer and international regulatory expectations," said Matthias Hackl, Co-Founder and CEO of TAmiRNA. ISO 13485:2016 is an internationally recognized quality systems standard tailored to the development and manufacturing of medical devices, including in-vitro diagnostic tests. This certification represents an important milestone for our company, and reflects our rigorous and risk-based approach [...]

30 01, 2023

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

2023-03-10T08:28:49+01:00January 30th, 2023|biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Comments Off on Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper

17 01, 2023

Biogenity Joins Forces with TAmiRNA

2023-03-10T08:29:26+01:00January 17th, 2023|biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Comments Off on Biogenity Joins Forces with TAmiRNA

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release

28 10, 2022

miND spike-in

2023-03-10T10:13:11+01:00October 28th, 2022|microRNA, NGS, smallRNA|Comments Off on miND spike-in

TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving  absolute quantitation of miRNAs across different biological matrix and species. click here for more Information on the miND spike-ins

Go to Top